2 completed, 1 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
Follow NFlection Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 12-week Study of NFX-179 Gel in Subjects With Epidermal Nevi NFX-179 Gel 1.50% - Epidermal Nevi, Nevus Sebaceus | Phase 2 | Withdrawn | Albert Chiou | 2023-06-01 | 2024-05-28 | |
| NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) NFX-179 gel, Vehicle gel - Cutaneous Neurofibroma, Neurofibromatosis 1 | Phase 2 | Completed | NFlection Therapeutics, Inc. | 199 | 2021-09-29 | 2026-02-17 |
| NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) NFX-179 Gel, Vehicle Gel - Neurofibromatosis 1, Cutaneous Neurofibroma | Phase 2 | Completed | NFlection Therapeutics, Inc. | 48 | 2020-08-21 | 2022-08-09 |
Neurofibromatosis 1 (2) · Nevus, Sebaceous of Jadassohn (1)
United States (3)
Albert S Chiou, MD, MBA (1) · Guy Webster, MD, PhD (1)